Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 39Gynecologic 3Genitourinary 3Thoracic 2Other hematologic neoplasm 2Breast 2Plasma cell 1Other solid neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 2Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × incomplete Freund's adjuvant × Gynecologic × Clear all
NCT01673217 2022-08-01

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Roswell Park Cancer Institute

Phase 1 Completed
18 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00001827 2017-10-06

p53 Vaccine for Ovarian Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
21 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT00091273 2014-06-20

Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

University of Virginia

Phase 1 Completed
9 enrolled 7 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡